Oruka Therapeutics

ORKANasdaq United States Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$6.183 B

$93.38 -1.66%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

-$105.4M

Loss-making

Shares outstanding

66,209,699

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances, ranked by market cap

All 19 →

#1Idexx LaboratoriesIDXX$40.6B
#2LantheusLNTH$6.55B
#3Oruka TherapeuticsORKA$6.18B
#4Celldex TherapeuticsCLDX$2.98B
#5NeogenNEOG$2.97B

What if Oruka Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.3T

$457,245.00

Per share 4,897× higher

Bitcoin $1.72T

$25,975.10

Per share 278× higher

Nvidia $5.48T

$82,765.19

Per share 886× higher

Or at a round number

$10.0B $20.0B $50.0B $100.0B

Where these numbers come from

Share counts and financials for Oruka Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.